Share on StockTwits
 

Investment analysts at Oppenheimer lifted their price target on shares of Cepheid (NASDAQ:CPHD) from $43.00 to $54.00 in a note issued to investors on Friday, AnalystRatingsNetwork.com reports. Oppenheimer’s price objective indicates a potential upside of 2.16% from the company’s current price.

A number of other analysts have also recently weighed in on CPHD. Analysts at UBS AG raised their price target on shares of Cepheid from $48.00 to $55.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. Separately, analysts at ISI Group raised their price target on shares of Cepheid from $38.00 to $39.00 in a research note to investors on Friday. Finally, analysts at Cowen and Company raised their price target on shares of Cepheid from $52.00 to $53.00 in a research note to investors on Friday. One analyst has rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating to the company. Cepheid has an average rating of “Hold” and a consensus price target of $48.25.

Cepheid (NASDAQ:CPHD) opened at 52.86 on Friday. Cepheid has a 52 week low of $30.95 and a 52 week high of $54.45. The stock has a 50-day moving average of $47.00 and a 200-day moving average of $40.85. The company’s market cap is $3.586 billion.

Cepheid (NASDAQ:CPHD) last posted its quarterly earnings results on Friday, January 31st. The company reported ($0.15) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.11) by $0.04. The company had revenue of $113.30 million for the quarter, compared to the consensus estimate of $102.17 million. On average, analysts predict that Cepheid will post $0.01 earnings per share for the current fiscal year.

Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical market, as well as for application in its legacy Non-Clinical market.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.